BLA 022175 · Digestive Care INC
Pertzye
Pancrelipase (Amylase, Lipase, Protease) · Oral
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
May 17, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
3,036
2,620 serious, 297 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 11, 2024.
PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )
Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 2012 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewPediatric Clinical Pharmacology Review
4 products under this application
- PERTZYE · PANCRELIPASE (AMYLASE 90,750USP UNITS; LIPASE 24,000USP UNITS; PROTEASE) 86,250USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PERTZYE · PANCRELIPASE (AMYLASE 60,500USP UNITS; LIPASE 16,000USP UNITS; PROTEASE) 57,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PERTZYE · PANCRELIPASE (AMYLASE 15,125USP UNITS; LIPASE 4,000USP UNITS; PROTEASE) 14,375USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PERTZYE · PANCRELIPASE (AMYLASE 30,250USP UNITS; LIPASE 8,000USP UNITS; PROTEASE) 28,750USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea262
- nausea173
- dyspnoea148
- fatigue144
- infective pulmonary exacerbation of cystic fibrosis137
- off label use134
- vomiting132
- pneumonia130
- abdominal pain122
- cough120
- pyrexia120
- asthenia117
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 12 |
| 2009 | 21 |
| 2010 | 45 |
| 2011 | 49 |
| 2012 | 51 |
| 2013 | 65 |
| 2014 | 62 |
| 2015 | 101 |
| 2016 | 123 |
| 2017 | 121 |
| 2018 | 189 |
| 2019 | 297 |
| 2020 | 278 |
| 2021 | 259 |
| 2022 | 297 |
| 2023 | 293 |
| 2024 | 295 |
| 2025 | 277 |
| 2026 | 140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pertzye (Lipase/Protease/Amylase)
2024 spending
$6.6M
Beneficiaries
382
1,733 claims
Per beneficiary
$17,200
$6.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,598,177 |
| 2021 | $4,579,812 |
| 2022 | $5,484,305 |
| 2023 | $6,564,873 |
| 2024 | $6,570,457 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Assessment of pancreatic exocrine insufficiency and pancreatic enzyme dose-response using the 13C-Mixed triglyceride breath test.
Cook ME, Campbell D, Køhler M, et al. · Scand J Gastroenterol 2026 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Digestive Care INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.